SEDG plunged approximately -25.21% during regular trading on Wednesday, falling from a prior close of $48.76 to an intraday low near $36.47, after the company reported Q2 2026 results premarket. The selloff was triggered by disappointing Q3 revenue guidance of $310M–$340M, well below the $371M analyst consensus — a roughly -12.6% miss at the midpoint — despite Q2 revenue and EPS both beating estimates.

TBLA plunged approximately -26.5% during Wednesday's regular session after gapping down sharply in premarket trading, falling from a prior close of $5.29 to near $3.89. The selloff was triggered by Q2 2026 earnings: revenue of $476.8M missed the $499.4M consensus, and adjusted EPS of $0.01 badly missed the $0.05 estimate.

SPY tracks the S&P 500 Index, providing market-cap-weighted exposure to roughly 500 of the largest publicly traded U.S. companies across all 11 GICS sectors. The fund is heavily concentrated in information technology (approximately 34% of assets), making its performance highly sensitive to mega-cap tech earnings, AI-related investment sentiment, and semiconductor industry dynamics.

DVA tumbled -14.91% intraday on August 5, extending a -6.5% after-hours decline on August 4 after the company reported Q2 2026 results. Q2 adjusted EPS of $4.02 and revenue of $3.55B both beat consensus estimates, but the top-and-bottom-line beat was overshadowed by cautious forward commentary.

NYT shares tumbled -13.36% to approximately $65.51 following its Q2 2026 earnings release, with the selloff igniting in premarket trading and accelerating during the regular session. Digital-only subscriber additions came in at 280,000, missing the ~295,300 consensus estimate and decelerating from 310,000 in Q1, fueling concerns over slowing growth momentum.

RRX shares plunged -12.94% to $191.56 during regular trading after the company reported Q2 CY2026 results that missed revenue expectations and issued full-year guidance below consensus. Revenue came in at $1.56 billion, missing analyst estimates of $1.58 billion, while organic revenue growth of just +3.3% also fell short of expectations.

CDW shares plunged -15.83% in regular trading to $129.62 from a prior close of $154.00, following a steep premarket selloff that persisted after the open. Q2 results released before the bell topped estimates — revenue of $6.57B (+10% YoY) and adjusted EPS of $2.91 — but gross margin contracted to 20.1%, well short of the 21.2% consensus.

MDLN shares fell -11.67% during regular trading on Wednesday after the company reported Q2 2026 earnings that revealed a 58.3% year-over-year drop in net income to $139 million. The steep profit decline was driven by $336 million in losses from a fire that destroyed its 1-million-square-foot distribution center in Tracy, California, before expected insurance recoveries.

SPCX plunged -10.28% during Wednesday's regular session, falling to $112.44 from Tuesday's close of $125.33, as investors reacted to the company's first-ever quarterly earnings as a public company. The sell-off was driven by SpaceX's Q2 results released after Tuesday's close: despite a revenue beat ($78B vs. $68.1B consensus), operating metrics disappointed — only 38 rocket launches versus 43 expected and payload mass well below Street estimates.

Galaxy Digital Holdings (GLXY) declined approximately 12.8% over the past 30 days, falling from a close of $25.40 on July 6, 2026, to $22.14 as of August 4, 2026. A $3.507 billion senior secured notes offering to fund the Helios Phase II data center expansion triggered significant leverage concerns among investors.

Eli Lilly shares pulled back roughly 5% from early July all-time highs near $1,249, closing at $1,148.84 on July 31, as investors position ahead of the August 5 Q2 2026 earnings report. The core GLP-1 franchise — Mounjaro and Zepbound — generated $12.82 billion in combined Q1 revenue, about 65% of total sales, and remains the central driver of the investment thesis.

Capricor Therapeutics (CAPR) shares plummeted approximately 81% over the past 30 days, falling from $22.43 on July 6 to $4.17 by August 4, 2026. The collapse was triggered by an FDA briefing document released July 27 that challenged the statistical validity of Deramiocel's Phase 3 HOPE-3 trial results, contradicting Capricor's earlier positive characterization.

First Tracks Biotherapeutics shares surged approximately 130% over the past 30 days, climbing from around $20.04 on July 6 to $46.01 by August 4, 2026. The stock hit multiple all-time highs during the period, driven by a powerful combination of clinical validation catalysts, analyst upgrades, and favorable sector momentum in biotech.

Forte Biosciences (FBRX) surged approximately 266% over the past 30 days, climbing from around $20.92 to $76.56 as of August 4, 2026. The primary catalyst was positive Phase 1b vitiligo data for lead candidate FB102, which sent shares soaring 78% in a single session on July 9.

Ibotta (IBTA) shares climbed approximately 13.2% over the last 30 days, propelled by a massive single-day surge following stronger-than-expected Q2 2026 earnings. The company reported revenue of $88.91 million, returning to year-over-year growth for the first time since Q1 2025, and delivered adjusted EBITDA of $16.5 million — 58% above the midpoint of its own guidance.

CG Oncology (CGON) is a late-stage clinical biopharmaceutical company focused on developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. The stock has traded in a relatively contained range over the past 30 days, with a modest gain of approximately 3%, reflecting a period of consolidation following stronger year-to-date gains.

Net profit surged 75.6% to 1.48 trillion yen ($9.4 billion) in Q1 FY2027, handily beating the consensus estimate of approximately 978 billion yen, though the jump was driven largely by currency gains and non-operating income rather than core automotive performance. Operating income declined 8.8% to 1.06 trillion yen, marking the fifth consecutive quarter of year-over-year operating profit contraction. The operating margin narrowed to 7.9% from 9.5% a year earlier.

Arista Networks delivered its first-ever $3 billion revenue quarter , reporting Q2 2026 revenue of $3.036 billion, up 37.7% year-over-year. Non-GAAP diluted earnings per share (EPS) came in at $1.02 , handily beating the consensus analyst estimate of approximately $0.88 to $0.89.

Revenue exceeded expectations: Merck posted second-quarter 2026 sales of $16.6 billion, up 5% year over year and ahead of the $16.41 billion consensus estimate. Non-GAAP EPS beat convincingly: The company reported an adjusted loss of $0.13 per share, significantly better than the $0.27 loss Wall Street had forecast.

HSBC reported second-quarter profit before tax of $10.1 billion , a 60% year-over-year surge that comfortably beat the consensus estimate of $9.51 billion. Revenue climbed to $19.1 billion , exceeding analyst forecasts of $18.51 billion, driven by strong wealth management fees and higher net interest income.